Table 2 Results of univariate and multivariate analysis for cancer-specific survival
From: Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma
| Variable | Three-year survival rate (%) | Univariate | Multivariate | |
|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | ||
| Age (<70/≥70 years) | 56.6/39.4 | 0.04 | 1.54 (0.67–3.41) | 0.30 |
| Sex (M/F) | 42.8/53.6 | 0.45 | ||
| Tumor diameter (<3cm/≥3cm) | 61.0/31.0 | <0.01 | 1.47 (0.71–3.12) | 0.30 |
| Lymph node metastasis (+/−) | 35.2/54.5 | 0.03 | 1.29 (0.64–2.60) | 0.47 |
| Stage (I/II) | 78.5/34.3 | <0.01 | 1.84 (0.71–5.20) | 0.21 |
| Differentiation (well, mod/por) | 50.2/36.7 | 0.08 | ||
| Lymphatic invasion (+/−) | 37.9/64.8 | 0.01 | 3.66 (1.56–9.49) | <0.01 |
| Venous invasion (+/−) | 44.0/58.0 | 0.12 | ||
| CEA (<5/≥5 ng/mL) | 49.3/33.9 | 0.48 | ||
| CA19-9 (<37/≥37 U/mL) | 74.7/35.0 | <0.01 | 3.39 (1.43–9.29) | <0.01 |
| Frailty (+/−) | 20.1/55.7 | <0.01 | 2.94 (1.36–6.40) | <0.01 |
| mGPS (0/1, 2) | 60.1/14.8 | <0.01 | 2.36 (1.08–5.10) | 0.03 |
| PNI (<40/≥40) | 66.7/89.4 | 0.34 | ||
| R0/R1 | 53.8/27.9 | 0.02 | 2.06 (0.94–4.45) | 0.07 |